- Home
- RNA vs PRLD Comparison
RNA vs PRLD Comparison
Compare RNA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | PRLD |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.6M | 218.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNA | PRLD |
|---|---|---|
| Price | $13.72 | $4.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 3 |
| Target Price | ★ $69.26 | $4.67 |
| AVG Volume (30 Days) | ★ 381.5K | 223.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $88.12 | $320.10 |
| Revenue Next Year | $18.11 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $11.95 | $0.65 |
| 52 Week High | $73.06 | $4.82 |
Technical Indicators
Market Signals| Indicator | RNA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 15.22 | 66.13 |
| Support Level | $13.06 | $1.02 |
| Resistance Level | $72.89 | N/A |
| Average True Range (ATR) | 0.50 | 0.39 |
| MACD | 2.01 | 0.08 |
| Stochastic Oscillator | 74.12 | 65.49 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.